
Do you eat a meal in 20 minutes or less? It might be time to slow down
If you're the kind of person who can regularly polish off breakfast, lunch or dinner in less than 20-30 minutes, you are eating too fast.
Advertisement
'It takes about 20 minutes for the stomach to communicate to the brain via a whole host of hormonal signals that it's full,' said Leslie Heinberg, at the Center for Behavioral Health at the Cleveland Clinic. 'So when people eat rapidly, they can miss these signals and it's very easy to eat beyond the point of fullness.'
Get Love Letters: The Newsletter
A weekly dispatch with all the best relationship content and commentary – plus exclusive content for fans of Love Letters, Dinner With Cupid, weddings, therapy talk, and more.
Enter Email
Sign Up
Why is that a problem?
People who eat quickly are likely to swallow more air, Heinberg said, which could lead to bloating or indigestion. Not chewing your food properly can also compromise digestion, meaning you won't get all of the nutrients from your food. Unchewed pieces of food also could get stuck in your esophagus.
Some previous studies have suggested that people who eat quickly have the highest risk of obesity, while the slowest eaters were the least likely to be obese.
How can you slow down when eating?
For starters, turn off the TV and put down your phone.
'If you're eating while you watch TV, people tend to eat until there's a commercial or the show is over,' Heinberg said, adding that people are less inclined to pay attention to the body's own signals that it's full. 'When we do things while we're eating, we're eating less mindfully. And that often causes us to eat more.'
She said that when people focus exclusively on eating, they tend to enjoy the meal more and eat less.
Heinberg also acknowledged the pace at which you eat is often an ingrained habit, but said change is still possible. She suggested things like using your non-dominant hand to eat, trying utensils you might not ordinarily use like chopsticks or taking a deliberate break to drink water when your plate is partially empty.
Advertisement
If you have a busy life, it might be unavoidable to eat lunch at a work meeting or snack while running errands. But Sarah Berry, chief scientist at the British nutritional company ZOE, said when possible, 'be mindful of what the food tastes and feels like.'
'If we're not fully present, it's very easy to eat more quickly and not notice how much we've consumed,' Berry said.
Chew your food, just like mom told you to
One of the simplest things to do is to increase the number of bites you take, said Helen McCarthy, a clinical psychologist with the British Psychological Society.
'If you chew each mouthful a little bit longer, that will slow down your eating,' she said.
The kind of food you eat may also make a difference, pointing out that it's much easier to eat ultraprocessed or fast foods quicker, because they typically have a softer texture.
'It's hard to eat vegetables and protein at the same rate as something that's highly processed and requires less chewing,' McCarthy said.
Some of her patients also reported an unintentional side effect once they began eating more slowly, referencing one woman who often ate a tube of potato chips every evening. When McCarthy told her to slow down and eat every single chip individually, her patient told her 'it was like having a mouthful of claggy chemicals.'
'She didn't find (the chips) enjoyable anymore,' McCarthy said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
HRT ‘can raise breast cancer risk' in younger women
Hormone replacement therapy can raise the risk of breast cancer in some younger women, a Lancet study suggests. An international team of researchers found the treatment was not linked to young onset breast cancer overall. But oestrogen plus progestin therapy appears to increase breast cancer risk by 10 per cent. Meanwhile, oestrogen hormone therapy use appeared to decrease breast cancer risk by 14 per cent. Hormone replacement therapy is a treatment used to help menopause symptoms. There are different types of HRT, which is used to treat menopause symptoms, available. They contain different hormones: some are oestrogen products; others contain progestogen and other types have both. These medicines can be taken or used in different ways and work by replacing the hormones oestrogen and progesterone, which can fall to lower levels as women approach the menopause. Most studies examining links between hormone therapy and breast cancer risk have been explored in older women. Previous work, which has focused on women who have already been through the menopause, suggest that oestrogen plus progestin hormone therapy is a risk factor for breast cancer. The researchers, led by academics from the National Institute of Environmental Health Sciences in the US, wanted to explore the risks among younger women on hormone therapy – who may take these drugs after gynaecological surgery or during perimenopause. The new meta-analysis published in the journal, Lancet Oncology, examined data drawn from previous studies of 459,476 women aged 16 to 54 years old. Some two per cent of this group (8,455) developed young-onset breast cancer, which means the disease was diagnosed before they were 55 years old. And 15 per cent of women involved in the study reported using hormone therapy, with oestrogen plus progestin hormone therapy and oestrogen being the most common types. 'Although the strength of these associations might vary by age at first use, duration of use, gynaecological surgery status, and other factors, unopposed oestrogen hormone therapy use appears to decrease breast cancer risk and oestrogen plus progestin therapy appears to increase breast cancer risk,' the authors wrote. 'The findings can be used to augment clinical recommendations for hormone therapy use in young women, for whom guidance was previously scarce.' Dr Kotryna Temcinaite, the head of research communications at Breast Cancer Now, said: 'These results are largely in line with what we already know about taking HRT for menopausal symptoms and its effects on breast cancer risk – for most people, the risk of developing breast cancer because of taking HRT is small and is outweighed by the benefits. 'Taking HRT is a very personal decision and, as such, it's vital that everyone has the information they need on the benefits and risks, discusses them with their GP or specialist team and is supported to make the choice that's right for them.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.


CNBC
4 hours ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
Yahoo
16 hours ago
- Yahoo
Three former bosses of UK nurse Lucy Letby, convicted of killing babies, arrested on suspicion of manslaughter
Three people who were part of the senior leadership team at the hospital where nurse and convicted child serial killer Lucy Letby worked have been arrested on suspicion of gross negligence manslaughter, British police said Tuesday. The three senior staff members, who have not been named by police, worked at the Countess of Chester Hospital in 2015 and 2016 at the same time as Letby. All three suspects have been released on bail after being questioned by police on Monday. 'It is important to note that this does not impact on the convictions of Lucy Letby for multiple offences of murder and attempted murder,' Cheshire Constabulary Detective Superintendent Paul Hughes said in a statement. The aspect of the investigation related to the latest arrests focuses on the 'grossly negligent action or inaction of individuals,' police said. Meanwhile, another ongoing part of the investigation into the separate offence of corporate manslaughter 'focuses on senior leadership and their decision making to determine whether any criminality has taken place concerning the response to the increased levels of fatalities.' Letby, 34, was found guilty of murdering seven children and attempting to murder seven more between June 2015 and June 2016 while working in the neonatal unit of the hospital in Chester, England. The former nurse is serving 15 whole-life sentences. The court heard during the case in 2023 that Letby attacked babies in her care by administering air into their blood and stomachs, overfeeding them with milk, physically assaulting them, and poisoning them with insulin. However, her convictions have been criticized after an international panel of experts raised questions regarding the medical evidence. The panel said there was no medical evidence indicating murder and that the babies' collapses resulted from 'either natural causes or bad medical care.' It also highlighted issues of unsafe delays in diagnosis and treatments at Countess of Chester Hospital and said that in some cases staff were working 'probably beyond their expected ability or designated level of care,' according to the British Medical Journal (BMJ). Last week, former UK Health Secretary Jeremy Hunt called for an 'urgent reexamination' after experts raised 'serious and credible' questions. Independent experts 'are saying there is no medical evidence in the 17 deaths that were examined in the trial of what they call maleficence, of malicious intent,' Hunt said in an interview with Good Morning Britain, calling for a speedy review by the UK's Criminal Cases Review Commission. 'If they are saying that, then I really think we need to do this.' 'I am not arguing that Letby is innocent. That is not my place… The pain endured by the families affected must also be at the forefront of our minds,' Hunt wrote in a separate op-ed published in the Daily Mail newspaper last month, arguing that the families deserve the truth. 'And if medical error was the cause, we can then make sure no more babies die from the same mistakes.' Letby has maintained her innocence and her lawyer Mark McDonald submitted an application earlier this year for her case to be reviewed by the commission. Letby's previous attempts to overturn her convictions have been refused by the court. McDonald told the UK's PA Media on Tuesday that a proper and full public inquiry into failings by the hospital's neonatal and pediatric medical care unit is needed. 'The concerns many have raised will not go away, and we will continue to publicly discuss them,' McDonald said, according to PA. 'The reality is that 26 internationally renowned experts have looked at this case and the lead expert has concluded that no crime was committed, no babies were murdered.' A public government inquiry is set to be published in early 2026. That inquiry previously heard evidence from the senior hospital leadership about the concerns raised regarding the rise in infant deaths at the neonatal unit, and the actions taken as a result. Cheshire Police said they were continuing to investigate 'the deaths and non-fatal collapses of babies at the neo-natal units of both the Countess of Chester Hospital and the Liverpool Women's Hospital,' at which Letby undertook training placements. The elements of the investigation related to corporate manslaughter and gross negligence manslaughter are also ongoing, police said. A spokeswoman for the Countess of Chester Hospital said it 'would not be appropriate' for the hospital to comment due to 'the ongoing police investigations' and public inquiry, PA reported.